BioHarvest Sciences, a pioneer in botanical synthesis, recently revealed its financial results for the second quarter of 2026, indicating a significant strategic reorientation. The company is actively moving towards high-margin contract development and manufacturing organization (CDMO) opportunities, while simultaneously adjusting its revenue expectations for the year downwards. A notable achievement reported is the securing of its inaugural commercial supply agreement for an exclusive fragrance compound, alongside outlining its intentions to reach consolidated EBITDA breakeven by 2027. Furthermore, BioHarvest Sciences Inc. (BHST) highlighted advancements in its sweetener and saffron development initiatives. The company affirmed its commitment to prudent cash management, aiming to circumvent the need for extra equity funding. Continuous investment in industrial automation and machine learning is central to enhancing its Botanical Synthesis technology platform.
BioHarvest Sciences Forges Ahead with Strategic Shift and Innovation in Q2 2026
On Tuesday, August 11, 2026, at 8:00 a.m. ET, BioHarvest Sciences hosted its Second Quarter 2026 Earnings Call. The call featured key participants including Chairman and Chief Executive Officer, Zaki Rakib; Chief Financial Officer, Bar Dichter; and Controller, Roi Atsaraf. The financial overview revealed a revenue of $8.8 million for Q2 2026, marking a 3.8% increase from $8.5 million in the previous year, with contributions from nutraceuticals and the CDMO sector. Gross profit reached $5.1 million, maintaining a 58% margin. The net loss improved to $3.7 million, or $0.17 per share, from $4.1 million, or $0.24 per share, in Q2 2025. However, the adjusted EBITDA loss increased to $1.6 million, attributed to heightened investments in CDMO development and a new marketing approach. Cash and cash equivalents dramatically rose to $16.2 million as of June 30, 2026, from $3.7 million a year prior.
A landmark announcement was the securing of a fragrance CDMO contract, projecting between $20 million to $30 million in potential revenue from 2027 to 2028, involving a 20-ton commitment for a rare fragrance compound. The total revenue guidance for 2026 was revised to $37 million to $40 million, down from $42 million to $48 million, due to strategic resource reallocation. Similarly, VINIA's revenue guidance was adjusted to $33 million to $35 million, with marketing spend redirected towards manufacturing capacity and CDMO growth, leading to an anticipated VINIA EBITDA loss of $1.5 million to $2.5 million. CDMO revenue guidance was tightened to $4 million to $5 million, focusing on high-value projects, with a reduced EBITDA loss forecast of $1.5 million to $2.5 million. The consolidated EBITDA loss guidance for 2026 stands at $3 million to $5 million. VINIA maintained approximately 95,000 active customers, experiencing a 2% growth year-over-year and quarter-over-quarter. A pricing increase of up to 20% was implemented for new subscription customers from their second order. Additionally, BioHarvest secured a $1.125 million agreement for Stage 2 saffron development and received a $1.4 million grant from the Israel Innovation Authority for advancements in data science and machine learning. Operating expenses totaled $7.6 million, up from $6.9 million, driven by technology development in the CDMO unit.
During the call, CEO Zaki Rakib underscored the fragrance contract as a pivotal validation of the company's technology, highlighting its focus on a highly valued, rare scent. He noted the project's accelerated timeline, with production slated to commence in early 2027. BioHarvest also expanded its collaboration with Tate & Lyle to encompass multiple plant-based sweetener molecules. The company plans to introduce single-dose VINIA Daily Chews in September, targeting a younger demographic and aiming for improved customer retention. Rakib emphasized a licensing model for high-volume products, where partners establish their own facilities, utilizing BioHarvest's technology and paying royalties. The Israel Innovation Authority grant is set to transform plant cell culture into a data-driven optimization framework. For the foreseeable future, BioHarvest intends to concentrate on VINIA and making other developed assets available to CDMO customers, rather than launching new proprietary products.
From a journalist's perspective, BioHarvest Sciences' decisive strategic pivot is a compelling narrative of adaptation and focused growth. The company's move to prioritize high-margin CDMO services, particularly exemplified by the significant fragrance contract, demonstrates a pragmatic approach to optimizing its unique Botanical Synthesis technology. This strategic shift, coupled with continued investment in AI and machine learning for biological workflows, positions BioHarvest to potentially unlock substantial value from its innovative platform. While the downward revision of revenue guidance might initially seem concerning, the underlying rationale of reallocating resources to areas with higher long-term profitability, and aiming for EBITDA breakeven without external equity, speaks volumes about management's confidence and commitment to financial discipline. The expansion of partnerships and product diversification, like the VINIA Daily Chews and the broader sweetener collaboration, signals a well-rounded strategy to capture different market segments. This approach could serve as a blueprint for other biotech companies navigating competitive landscapes: to hone in on core competencies, leverage existing intellectual property strategically, and innovate relentlessly to create sustainable value.
